News and Updates
Overview of Lupus ABC’s Year One Accomplishments and Second Annual Meeting
June 13, 2024
The Lupus Accelerating Breakthroughs Consortium (Lupus ABC) is pleased to report on the progress made during its inaugural year, culminating in the successful second annual meeting held on April 15-16 in Bethesda, Maryland. Lupus ABC is a first-of-its-kind public-private partnership (PPP) uniting individuals with lupus and their advocates, industry, clinicians, researchers, and government stakeholders to collaboratively identify and pursue the most effective ways to accelerate the development of urgently needed personalized treatments for people with lupus.
Lupus Accelerating Breakthroughs Consortium Announces Expanded Partnership with U.S. FDA at First Anniversary Meeting
April 16, 2024
Center for Biologics Evaluation and Research Joins Consortium to Accelerate Engineered Cell Therapies for Lupus
The Lupus Research Alliance (LRA), founder and administrator of the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), announced today at the Consortium’s first anniversary meeting an expanded partnership with the U.S. Food and Drug Administration (FDA) with the inclusion of the Center for Biologics Evaluation and Research (CBER). The addition of CBER to Lupus ABC will enhance the Consortium’s focus on engineered cell therapies, a promising new area in lupus therapeutic development. Lupus ABC was launched in collaboration with the FDA Center for Drug Evaluation and Research (CDER) in March 2023.
Overview of Lupus ABC Inaugural Meeting April 16-17, 2023
April 17, 2023
The Lupus Research Alliance is pleased to report that the Lupus Accelerating Breakthroughs Consortium (Lupus ABC) held its inaugural meeting on April 16-17 in Bethesda, Maryland. Lupus ABC is the first public-private partnership with the U.S. Food and Drug Administration (FDA) to focus specifically on advancing the development of safer and more effective treatments urgently needed for people with lupus. The goal of the Lupus ABC is to bring together people with lupus, federal agencies, medical societies, advocacy groups, industry, academic clinical researchers, and scientists, with the FDA, to overcome scientific hurdles in drug development that are beyond the capacity of any single entity. This meeting was an important first step in formally constituting the Consortium and serves as a launching point for continued community outreach and engagement. In addition to an open plenary session, the first individual meetings of the two main governing committees of the Consortium were held to set the strategy for the Lupus ABC – the Lupus Voices Council (LVC) and the Research Committee (RC).
FDA launches Lupus Treatment Consortium in partnership with the Lupus Research Alliance
March 29, 2023
FDA’s Center for Drug Evaluation and Research has partnered with the Lupus Research Alliance (LRA) to launch the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), a first-of-its-kind public-private partnership focused on addressing challenges impacting lupus clinical trial success.
Lupus Research Alliance Unites the U.S. Food & Drug Administration (FDA) & Lupus Community to Launch Novel Public-Private Partnership
March 29, 2023
The Lupus Research Alliance (LRA) today announced the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), a first-of-its-kind public-private partnership bringing people with lupus together in collaboration with the U.S. Food and Drug Administration (FDA), other federal agencies, medical societies, industry, academic clinical researchers and scientists to overcome scientific hurdles that are beyond the capacity of any single entity and to advance the development of urgently needed, personalized treatments for lupus.